Article Figures & Tables
Tables
Characteristic No. (%)* Age, yr, mean ± SD 60.8 ± 10.0 Tumour size, mm, mean ± SD, median (range) 17 ± 13, 15 (0–110) Specimen weight, g, mean ± SD, median (range) 155 ± 146, 110 (15–1132) Histology Invasive ductal carcinoma 237 (86.2) Invasive lobular carcinoma 15 (5.5) Ductal carcinoma in situ 18 (6.6) Other invasive (mucinous and papillary) 3 (1.1) Phyllodes 2 (0.7) Histologic subtype (invasive, n = 255) Luminal A 215 (84.3) ER/PR positive, HER2 positive 11 (4.3) ER/PR negative, HER2 positive 7 (2.7) Triple negative 22 (8.6) SBR grade (invasive, n = 255) I 92 (36.1) II 102 (40.0) III 52 (20.4) Missing 9 (3.5) Pathologic T stage (invasive, n = 255) pT1 168 (65.9) pT2 81 (31.8) pT3 4 (1.5) pT4 2 (0.8) Overall TMN stage (invasive, n = 255) I 140 (54.9) II 105 (41.2) III 10 (3.9) Nodal status (invasive, n = 255) Negative 175 (68.6) Positive 67 (26.3) Not assessed 13 (5.1) ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; PR = progesterone receptor; SBR = Scarff–Bloom–Richardson; SD = standard deviation.
↵* Unless indicated otherwise
Complication No. (%) Immediate Edema/swelling 90 (32.7) Wound infection 35 (13.1) Hematoma 24 (8.7) Delayed wound healing 18 (6.5) Skin-flap necrosis 3 (1.1) Nipple necrosis 2 (0.7) Long-term/delayed Reoperation for cosmesis 46 (16.7) Fat necrosis 14 (5.1) Inclusion cyst 3 (1.1) Inappropriate scarring 3 (1.1) Complication Patients without re-excision
n = 232Patients with re-excision
n = 43p value Seroma/edema 78 (33.6%) 12 (27.9%) 0.60 Wound infection 26 (11.2%) 10 (23.3%) 0.046 Hematoma 21 (9.1%) 3 (7.0%) 1.00 Delayed wound healing 13 (5.6%) 5 (11.6%) 0.17 Complication Procedure; no. (%) p value No axillary surgery
n = 22SLNB
n = 237ALND
n = 16Seroma/edema 5 (22.7) 82 (34.6) 3 (18.8) 0.25 ALND = axillary lymph node dissection; SLNB = sentinel lymph node biopsy.
Outcome No. (%) Local recurrence 9 (3.3) Distant recurrence 2 (0.7) Overall survival 273 (99.3)